Headlinne
Sign inGet Headlinne
Ars Technica·1 min read·medium

Martin Shkreli livestreamed himself violating lifetime pharma ban, FTC says

Beth Mole
✦AI Summary

The Federal Trade Commission (FTC) alleges that Martin Shkreli has violated a lifetime ban from the pharmaceutical industry by livestreaming himself discussing biotech stocks. Shkreli was previously barred from the industry following a fraud conviction.

Why it matters

This case tests the enforceability of regulatory bans on individuals in the pharmaceutical sector and the reach of government oversight into digital content.

✦Dive DeeperCreate a free account to unlock

"I can always find a couple of biotech…

Continue reading on Headlinne

Create a free account to read the full article.

Read full article →

Also covering this story

2 other newsrooms covered this event. We read each version separately.

QuartzBalanced

FTC and 7 states are seeking to hold Martin Shkreli in contempt over pharma ban

The GuardianNot placed

​FTC and seven states seek contempt ruling against Shkreli over pharma ban

businesshealth
Read originalGet full access
✦

Get smarter about the news

Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.

Create free account

Already have an account? Sign in